Teratology: General considerations and principles
Teratology: General considerations and principles
复制标题
DOI：
10.1016/s0091-6749(99)70259-9
复制
发表时间：
1999-02-01
影响因子：
14.2
通讯作者：
Finnell, RH
中科院分区：
文献类型：
--
作者：
Finnell, RH
在美国出生的儿童中，约有3%至5%表现出发育缺陷。这些出生缺陷中的2%至3%可归类为致畸剂诱导的畸形，其由妊娠期间的环境或医源性暴露引起。药物诱导的异常发育的最终表现可为死亡、畸形、生长迟缓或功能障碍。在考虑药物的潜在致畸作用时，重要的是要记住，对药物诱导的畸形的易感性取决于：（1）孕体的基因型，（2）暴露发生的发育阶段，（3）药物的作用机制，（4）药物进入发育组织的途径，以及（5）药物的剂量。如果致畸剂暴露的剂量反应关系和药物的致畸活性能够明确定义，几乎所有致畸剂诱导的出生缺陷都是可以预防的。
Approximately 3% to 5% of children born in the United States manifest developmental defects. Between 2% and 3% of these birth defects can be classified as teratogen-induced malformations, which result from environmental or iatrogenic exposures during pregnancy The final manifestations of drug-induced abnormal development can be death, malformation, growth retardation, or functional disorder. In considering the potential teratogenic effects of drugs, it is important to remember that susceptibility to a drug-induced malformation depends on: (1) the genotype of the conceptus, (2) the developmental stage at which exposure occurs, (3) the mechanisms of action of the drug, (4) the access of the drug to developing tissues, and (5) the dose of the drug. Nearly all teratogen-induced birth defects are preventable if the dose-response relationship for teratogen exposure and the teratogenic activity of the drug can be clearly defined.